Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

NCT02176135 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

HIV

Interventions

DRUG: Auranofin

Sponsor

Vaccine and Gene Therapy Institute, Florida

Collaborators

[object Object]